Hegg R, Mattar A, Matos-Neto JN de, Pedrini JL, Aleixo SB, Rocha RO, et al. A phase III, randomized, non-inferiority study comparing the efficacy and safety of biosimilar filgrastim versus originator filgrastim for chemotherapy-induced neutropenia in breast cancer patients . Clinics [Internet]. 2016 Oct. 1 [cited 2025 Apr. 30];71(10):586-92. Available from: https://www.revistas.usp.br/clinics/article/view/122233